Jaguar Health Board Initiates Review Of Strategic Alternatives To Maximize Shareholder Value, Aligned With Anticipated NDA Filing For Crofelemer Candidate In Rare Intestinal Failure Diseases

Loading news article.

Jaguar Health Board Initiates Review Of Strategic Alternatives To Maximize Shareholder Value, Aligned With Anticipated NDA Filing For Crofelemer Candidate In Rare Intestinal Failure Diseases | WAPE

Jaguar Health Board Initiates Review Of Strategic Alternatives To Maximize Shareholder Value, Aligned With Anticipated NDA Filing For Crofelemer Candidate In Rare Intestinal Failure Diseases

Article summary

Related companies

Comments —